MA hails drugs access

PEAK innovator medicines representatives group Medicines Australia (MA) has welcomed the government’s response to the Senate Community Affairs References Committee Report: ‘Availability of new, innovative and specialist cancer drugs in Australia’.

The report recommended improvements to and streamlining of existing regulatory and assessment processes for new medicines, with many of the issues currently being addressed through reforms of the Therapeutic Goods Administration (TGA).

“In particular, we look forward to the passage of legislation currently before Parliament that includes provisions for another expedited pathway called Provisional Approval that aims to speed up access to new medicines,” MA said.

“Not only does the Agreement provide Ψ1.8 billion in savings on PBS listed medicines that will be used to pay for new treatments, the Government has committed to reform that will improve and accelerate processes that lead to a medicine being made available on the PBS,” the organisation added. dark particles of silica.

It’s presumed the particles have been released from the dessicant cylinder that is placed inside the bottle to ensure the contents are kept dry.

The particles may be large enough to see as small specks, or simply appear as a dust that discolours the tablets and\or the inside of the bottle.

The potential contamination is classified as a quality defect and is not considered to impact product safety or efficacy.

Consumers are being advised to check the batch number and if it is from an affected batch, return it to a pharmacy for a refund or replacement.

Health problems are unlikely to be experienced as a result of the issue, the TGA said - more information at www.tga.gov.au.